Stock Track | Hims & Hers Health Soars 5.16% Intraday on Barclays Price Target Hike and Novo Nordisk Weight-Loss Drug Deal

Stock Track03-11

Hims & Hers Health Inc. (HIMS) stock surged 5.16% during intraday trading on Wednesday, driven by positive analyst sentiment and significant business developments.

The rally follows Barclays raising its price target on the telehealth company to $29 from $25, reflecting increased confidence in the company's prospects. This analyst action comes amid broader positive insights from healthcare sector analysts on Hims & Hers Health.

Investor enthusiasm is further fueled by the company's strategic partnership with Novo Nordisk to sell the pharmaceutical giant's blockbuster weight-loss drugs Wegovy and Ozempic on the Hims & Hers platform. This deal resolves previous legal disputes and marks a strategic shift for Hims & Hers toward focusing on branded medications. The company has reinforced this new direction by appointing a communications veteran from Eli Lilly to lead its branded weight-loss drug initiative.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1196169173?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-11 21:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1196169173","market":"sg","top_or_hot":-1,"title":"Stock Track | Hims & Hers Health Soars 5.16% Intraday on Barclays Price Target Hike and Novo Nordisk Weight-Loss Drug Deal","media":"Stock Track","content":"<p>Hims & Hers Health Inc. (HIMS) stock surged 5.16% during intraday trading on Wednesday, driven by positive analyst sentiment and significant business developments.</p><p>The rally follows Barclays raising its price target on the telehealth company to $29 from $25, reflecting increased confidence in the company's prospects. This analyst action comes amid broader positive insights from healthcare sector analysts on Hims & Hers Health.</p><p>Investor enthusiasm is further fueled by the company's strategic partnership with Novo Nordisk to sell the pharmaceutical giant's blockbuster weight-loss drugs Wegovy and Ozempic on the Hims & Hers platform. This deal resolves previous legal disputes and marks a strategic shift for Hims & Hers toward focusing on branded medications. The company has reinforced this new direction by appointing a communications veteran from Eli Lilly to lead its branded weight-loss drug initiative.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hims & Hers Health Soars 5.16% Intraday on Barclays Price Target Hike and Novo Nordisk Weight-Loss Drug Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hims & Hers Health Soars 5.16% Intraday on Barclays Price Target Hike and Novo Nordisk Weight-Loss Drug Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-11 21:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hims & Hers Health Inc. (HIMS) stock surged 5.16% during intraday trading on Wednesday, driven by positive analyst sentiment and significant business developments.</p><p>The rally follows Barclays raising its price target on the telehealth company to $29 from $25, reflecting increased confidence in the company's prospects. This analyst action comes amid broader positive insights from healthcare sector analysts on Hims & Hers Health.</p><p>Investor enthusiasm is further fueled by the company's strategic partnership with Novo Nordisk to sell the pharmaceutical giant's blockbuster weight-loss drugs Wegovy and Ozempic on the Hims & Hers platform. This deal resolves previous legal disputes and marks a strategic shift for Hims & Hers toward focusing on branded medications. The company has reinforced this new direction by appointing a communications veteran from Eli Lilly to lead its branded weight-loss drug initiative.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1196169173","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1196169173","pubTimestamp":1773236512,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Hims & Hers Health Inc. (HIMS) stock surged 5.16% during intraday trading on Wednesday, driven by positive analyst sentiment and significant business developments.The rally follows Barclays raising...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"个股追踪|Hims&Hers Health盘中大涨5.16%，因巴克莱目标价上调和诺和诺德减肥药交易","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"Hims & Hers Health Inc. (HIMS) stock surged 5.16% during intraday trading on Wednesday, driven by positive analyst sentiment and significant business developments.The rally follows Barclays raising its price target on the telehealth company to $29 from $25, reflecting increased confidence in the company's prospects. This analyst action comes amid broader positive insights from healthcare sector analysts on Hims & Hers Health.Investor enthusiasm is further fueled by the company's strategic partnership with Novo Nordisk to sell the pharmaceutical giant's blockbuster weight-loss drugs Wegovy and Ozempic on the Hims & Hers platform. This deal resolves previous legal disputes and marks a strategic shift for Hims & Hers toward focusing on branded medications. The company has reinforced this new direction by appointing a communications veteran from Eli Lilly to lead its branded weight-loss drug initiative.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1196169173","isCrawlerRequest":true}